NeuroFlow and Genomind are partnering on mental health services that incorporate pharmacogenomic testing to help guide treatment for a range of conditions, including anxiety, depression, post-traumatic stress disorder, and obsessive-compulsive disorder.
Philadelphia-based NeuroFlow markets a mobile app for smartphones that helps patients with mental health conditions track their wellness through journaling about their activities and fluctuations in mood. King of Prussia, PA-based Genomind markets the Genomind Professional PGx Express cheek swab test, which profiles the genetics of patients and helps clinicians make decisions about what medications to prescribe for mental health conditions.
The companies said that physicians using NeuroFlow's platform will now offer Genomind testing and results reporting on pharmacogenomic factors related to mental health and response to medications.
